Current Oncology, Volume 25, Issue 3

Cancer is a prevalent health condition that all physicians will frequently encounter during their clinical practice. [...]

The Canadian Lung Cancer Conference, held in Vancouver, 8–9 February 2018, was a successful, informative, and well-organized meeting. [...]

The era of immunotherapy and improved cancer treatments has led to current trends in health care [...]

Purpose: As cancer centres move forward with earlier discharge of stable survivors of early-stage breast cancer (BCA) to primary care follow-up, it is important to address known knowledge and practice gaps among primary care providers (PCPS). In the...

Background: In 2000, a Canadian task force recommended that medical oncologists (MOS) meet a target of 160–175 new patient consultations per year. Here, we report the Canadian results of a global survey of mo workload compared with mo workload in oth...

Background: Despite the high incidence and burden of cancer in Canadians, medical oncology (MO) rotations are not mandatory in most Canadian internal medicine (IM) residency training programs. Methods: All IM residents scheduled for a MO rotation at...

Background: A comprehensive assessment of cannabis use by patients with cancer has not previously been reported. In this study, we aimed to characterize patient perspectives about cannabis and its use. Methods: An anonymous survey about cannabis use...

Background: Because continued cigarette smoking after a cancer diagnosis is associated with detrimental outcomes, supporting cancer patients with smoking cessation is imperative. We evaluated the effect of the Smoking Cessation Program at the London...

Colorectal cancer (CRC) is the 2nd most common cancer in Canada and the 2nd leading cause of cancer death. That heavy burden can be mitigated given the preventability of crc through lifestyle changes and screening. Here, we describe the extent of the...

The 2018 Canadian Lung Cancer Conference (CLCCO) took place 8–9 February in Vancouver, British Columbia. A highly anticipated event, the CLCCO attracts lung cancer professionals from across Canada to review the latest advances in lung cancer research...

At the age of 34, I was diagnosed with follicular lymphoma. I had just finished my doctorate and was ready to launch into the world[...]

Background: Cancer-patient navigators who are oncology nurses support and connect patients to resources throughout the cancer care trajectory, including end of life. Although qualitative and cohort studies of navigated patients have been reported, no...

Malnutrition is a frequent manifestation in patients with head-and-neck cancer undergoing radiation therapy and a major contributor to morbidity and mortality. Thus, body composition is an important component of an overall evaluation of nutrition in...

Background: Some surgeons change gloves and instruments after the extirpative phase of cancer surgery with the intent of reducing the risk of local and wound recurrence. Although this practice is conceptually appealing, the evidence that gloves or in...

Checkpoint inhibitors targeting the programmed cell death 1 protein (PD-1) and programmed cell death ligand 1 (PD-L1) are demonstrating promising efficacy and appear to be well tolerated in a number of tumour types. In non-small-cell lung cancer, hea...

We report on a patient with an adenocarcinoma of the lung harbouring a BRAF V600E mutation who benefited from combination therapy with dabrafenib–trametinib after developing resistance to vemurafenib. To our knowledge, our report shows, for the first...

Anastomosing hemangioma (AH) is a rare subtype of primary vascular tumour that can, clinically and radiologically, present similarly to malignant renal tumours such as renal cell carcinoma (RCC) and angiosarcoma. Rarely seen in the genitourinary syst...

The comprehensive assessment of inherited mutations in cancer susceptibility genes helps to optimize clinical decision-making [...]